Analysis of V2 Antibody Responses Induced in Vaccinees in the ALVAC/AIDSVAX HIV-1 Vaccine Efficacy Trial

The RV144 clinical trial of a prime/boost immunizing regimen using recombinant canary pox (ALVAC-HIV) and two gp120 proteins (AIDSVAX B and E) was previously shown to have a 31.2% efficacy rate. Plasma specimens from vaccine and placebo recipients were used in an extensive set of assays to identify...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Zolla-Pazner, Susan, deCamp, Allan C., Cardozo, Timothy, Karasavvas, Nicos, Gottardo, Raphael, Williams, Constance, Morris, Daryl E., Tomaras, Georgia, Rao, Mangala, Billings, Erik, Berman, Phillip, Shen, Xiaoying, Andrews, Charla, O'Connell, Robert J., Ngauy, Viseth, Nitayaphan, Sorachai, de Souza, Mark, Korber, Bette, Koup, Richard, Bailer, Robert T., Mascola, John R., Pinter, Abraham, Montefiori, David, Haynes, Barton F., Robb, Merlin L., Rerks-Ngarm, Supachai, Michael, Nelson L., Gilbert, Peter B., Kim, Jerome H.
Formato: Artigo
Lenguaje:Inglês
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3547933/
https://ncbi.nlm.nih.gov/pubmed/23349725
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0053629
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares